Jeffrey Zurita

Mersana Therapeut

关注

立即认领

关注

立即认领

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy,Alex Uttard,Bingfan Du,Kalli C. Catcott,Kelly L. Lancaster,Elizabeth Ditty,Jack Sadowsky,Jeffrey Zurita,Naniye Malli,LiuLiang Qin, Stephen P. Bradley,Kenneth Avocetien,Tyler Carter,Dokyong Kim,Mark Nazzaro,Ling Xu,Thomas H. Pillow,Neelie T. Zacharias,Gail D. Lewis,Rebecca K. Rowntree,Radha Iyengar,David H. Lee,Marc Damelin,Dorin Toader,Timothy B. Lowinger

openalex（2024）

引用0浏览0引用

Figure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

openalex（2024）

引用0浏览0引用

Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

crossref（2024）

引用0浏览0引用

Table S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

openalex（2024）

引用0浏览0引用

Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy,Alex Uttard,Bingfan Du,Kalli C. Catcott,Kelly L. Lancaster,Elizabeth Ditty,Jack Sadowsky,Jeffrey Zurita,Naniye Malli,LiuLiang Qin,Stephen P. Bradley,Kenneth Avocetien,Tyler Carter,Dokyong Kim,Mark Nazzaro,Ling Xu,Thomas H. Pillow,Neelie T. Zacharias,Gail D. Lewis,Rebecca K. Rowntree,Radha Iyengar,David H. Lee,Marc Damelin,Dorin Toader,Timothy B. Lowinger

MOLECULAR CANCER THERAPEUTICS（2024）

引用0浏览0WOS引用

Figure S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

openalex（2024）

引用0浏览0引用

Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

openalex（2024）

引用0浏览0引用

Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios

crossref（2024）

引用0浏览0引用

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. R. Duvall,Joshua D. D. Thomas,Raghida A. A. Bukhalid,Kalli C. C. Catcott,Keith W. W. Bentley,Scott D. D. Collins,Timothy Eitas,Brian D. D. Jones,Eugene W. W. Kelleher,Kelly Lancaster,Marina Protopopova, Soumya S. S. Ray,Elena Ter-Ovanesyan,Ling Xu,Liping Yang,Jeffrey Zurita,Marc Damelin, Dorin Toader,Timothy B. B. Lowinger

Journal of medicinal chemistryno. 15 (2023): 10715-10733

引用3浏览0WOS引用

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall,Raghida A. Bukhalid,Naniye M. Cetinbas,Kalli C. Catcott,Kelly Lancaster,Keith W. Bentley,Suzanna Clark,Susan Clardy,Scott D. Collins,Anouk Dirksen,Elizabeth Ditty,Bingfan Du,Eugene W. Kelleher,Travis Monnell,Marina Protopopova,Caitlin Routhier,Cheri Stevenson,Elena Ter-Ovanesyan,Joshua D. Thomas,Alex Uttard,Jason Wang,Phonphimon Wongthida,Ling Xu, Annika Yau,Jeffrey Zurita, Dorin Toader,Marc Damelin,Timothy B. Lowinger

Cancer Researchno. 12_Supplement (2022): 3503-3503

引用3浏览0引用

加载更多

作者统计

#Papers: 16

#Citation: 37

H-Index: 3

G-Index: 6

Sociability: 4

Diversity: 1

Activity: 27

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn